Viral Hepatitis

You have full text access to this OnlineOpen article

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow responders†‡

  1. Brian L. Pearlman1,2,3,4,§,*,
  2. Carole Ehleben2,
  3. Sophia Saifee2

Article first published online: 28 NOV 2007

DOI: 10.1002/hep.21919

Issue

Hepatology

Hepatology

Volume 46, Issue 6, pages 1688–1694, December 2007

Additional Information

How to Cite

Pearlman, B. L., Ehleben, C. and Saifee, S. (2007), Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow responders. Hepatology, 46: 1688–1694. doi: 10.1002/hep.21919

Author Information

  1. 1

    Center For Hepatitis C, Atlanta Medical Center, Atlanta, GA

  2. 2

    Department Internal Medicine, Atlanta Medical Center, Atlanta, GA

  3. 3

    Department Internal Medicine, Medical College of Georgia, Augusta, GA

  4. 4

    Department Internal Medicine, Emory School of Medicine, Atlanta, GA

  1. §

    fax: 404-872-4061

*Center for Hepatitis C, Atlanta Medical Center, 315 Boulevard NE, Suite 200, Atlanta, GA 30309

  1. †

    Potential conflict of interest: Dr. Pearlman is on the speaker's bureau of Schering-Plough.

  2. ‡

    See Article on Page 1671.

Publication History

  1. Issue published online: 28 NOV 2007
  2. Article first published online: 28 NOV 2007
  3. Manuscript Accepted: 10 JUL 2007
  4. Manuscript Received: 6 APR 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (216K)

References

  • 1
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 35: 958–965.
  • 2
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis c virus infection. N Engl J Med 2002; 347: 975–982.
  • 3
    Jeffers L, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a and ribavirin for black American patients with chronic HCV genotype 1. HEPATOLOGY 2004; 39: 1702–1708.
    Direct Link:
  • 4
    Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites. N Engl J Med 2004; 350: 2265–2271.
  • 5
    Buti M, Valdes A, Sanchez-Avila F, Esteban R, Lurie Y. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. HEPATOLOGY 2003; 37: 1226–1227.
    Direct Link:
  • 6
    Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis c patients treated with peginterferon alfa-2a/ribavirin. J Hepatol 2005; 43: 425–433.
  • 7
    Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 645–652.
    Direct Link:
  • 8
    Berg T, Von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086–1097.
  • 9
    Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006: 131: 451–460.
  • 10
    National Institutes of Health Consensus Development Conference Statement: management of hepatitis C 2002. HEPATOLOGY 2002; 36: S3–S20.
    Direct Link:
  • 11
    Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alfa-2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis virus. J Infect Dis 2004; 189: 964–970.
  • 12
    Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon alfa-2b for 60 weeks. HEPATOLOGY 1994; 19: 280–285.
    Direct Link:
  • 13
    Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457–1462.
  • 14
    Brouwer JT, Nevens F, Bekkering FC, Bourgeois N, Van Vlierberghe H, Weegink CJ, et al. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. J Hepatol 2004; 40: 689–695.
  • 15
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.
  • 16
    Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. HEPATOLOGY 2003; 38: 639–644.
    Direct Link:
  • 17
    Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470–477.
  • 18
    Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5: 124–129.
  • 19
    Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132: 103–112.
  • 20
    Cooper CL, Al-Bedwawi S, Lee C, Garber G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006; 42: 1674–1678.
  • 21
    Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. HEPATOLOGY 2002; 36: 1273–1279.
    Direct Link:
  • 22
    Pearlman BL. Hepatitis C virus infection in African Americans. Clin Infect Dis 2006; 42: 82–91.
  • 23
    Buti M, Lurie Y, Blokhina N, Teuber G, Halota W, Sumskiene J, et al. Pegylated interferon alfa-2b plus ribavirin in patients with genotype 1 chronic hepatitis C with a slow virologic response: an early enrollers analysis of the SUCCESS Study [Abstract]. HEPATOLOGY 2006; 44( Suppl): 342A.
View Full Article (HTML) Get PDF (216K)